Open Access

Ocular adnexal lymphoma – a retrospective study and review of the literature

Lucka Boltezar

Lucka Boltezar

  • Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Boltezar, Lucka
, 
Danijela Strbac

Danijela Strbac

  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
  • Department of Radiotherapy, Institute of Oncology LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Strbac, Danijela
, 
Joze Pizem

Joze Pizem

  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
  • Institute of Pathology, Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Pizem, Joze
 and 
Gregor Hawlina

Gregor Hawlina

  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
  • Eye Hospital, University Medical Centre LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Hawlina, Gregor
  
Sep 15, 2024
Ocular adnexal lymphoma – a retrospective study and review of the literature's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Sep 15, 2024
Page range: 416 - 424
Received: Apr 30, 2024
Accepted: Aug 12, 2024
DOI: https://doi.org/10.2478/raon-2024-0048
Keywords
© 2024 Lucka Boltezar et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

Patient with conjunctival lymphoma presents with a characteristic salmon-pink nodular patch in the conjunctiva.
Patient with conjunctival lymphoma presents with a characteristic salmon-pink nodular patch in the conjunctiva.

FIGURE 2.

Patient with orbital lymphoma presents with a mass lesion within the right eye.
Patient with orbital lymphoma presents with a mass lesion within the right eye.

FIGURE 3.

Overall survival.
Overall survival.

FIGURE 4.

Lymphoma specific survival.
Lymphoma specific survival.

Treatment outcome in 58 patients with post-treatment evaluation, post-treatment evaluation being done three to six months after the end of treatment

Treatment outcome Number of patients
Complete remission 46 (79.3%)
Partial remission 10 (17.2%)
Stable disease 1 (1.7%)
Progressive disease 1 (1.7%)*

Patients’ characteristics

Males Females All
Number of patients 30 (40.5%) 44 (59.5%) 74
Median age, years 72 (range 41 – 89) 67.5 (range 34 – 89) 68
Lymphoma type
  - Marginal zone lymphoma (MALT) 21/30 (70.0%) 32/44 (72.7%) 53/74 (71.6%)
  - Mantle cell lymphoma (MCL) 6/30 (20.0%) 3/44 (6.8%) 9/74 (12.2%)
  - Follicular lymphoma (FL) 2/30 (6.7%) 4/44 (9.0%) 6/74 (8.1%)
  - Diffuse large B-cell lymphoma (DLBCL) 1/30 (3.3%) 3/44 (6.8%) 4/74 (5.4%)
  - Chronic lymphocytic leukemia (CLL) 0/30 (0%) 1/44 (2.3%) 1/74 (1.4%)
  - Peripheral T-cell lymphoma, not otherwise specified 0/30 (0%) 1/44 (1.4%) 1/74 (1.4%)
Conjunctival lymphoma 7/30 (23.3%) 11/44 (25.0%) 18/74 (24.3%)
Orbital lymphoma 23/30 (76.7%) 33/44 (75.0%) 56/74 (75.7%)

Specifications of orbital and conjunctival lymphomas

Orbital lymphomas Conjunctival lymphomas All
Unilateral lymphoma 46/56 (82.1%) 17/18 (94.4%) 63/74 (85.1%)
Bilateral lymphoma 10/56 (17.9%) 1/18 (5.6%) 11/74 (14.9%)
Lymphoma type
  - Marginal zone lymphoma (MALT) 36/56 (64.3%) 17/18 (94.4%) 53/74 (71.6%)
  - Mantle cell lymphoma (MCL) 9/56 (16.1%) 0/18 (0%) 9/74 (12.2%)
  - Follicular lymphoma (FL) 5/56 (8.9%) 1/18 (5.6%) 6/74 (8.1%)
  - Diffuse large B-cell lymphoma (DLBCL) 4/56 (7.1%) 0/18 (0%) 4/74 (5.4%)
  - Chronic lymphocytic leukemia (CLL) 1/56 (1.8%) 0/18 (0%) 1/74 (1.4%)
  - Peripheral T-cell lymphoma, not otherwise specified 1/56 (1.8%) 0/18 (0%) 1/74 (1.4%)
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed